LONA - LeonaBio, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

LONA

LEONABIO, INC.

NASDAQ

$8.00

▲ UP 1.39% (0.11)

KEY STATISTICS

Market Cap$31.55 M

52w High$11.91

52w Low$4.25

Dividend Yield—

Frequency—

P/E-0.32

Volume5.06K

Shares Out.3.94M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Mark J. Litton

COMPENSATION 2026

Salary$625,000

Stock Awards$83,720

Incentive Plan Pay$0

All Other Comp.$25,085

Total$1,423,814

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 18, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

PRICE TARGET

Target High$20.00

Target Low$15.00

Target Median$17.50

Target Consensus$17.50

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-09-18	Reverse	1:10

PRICE

$8.00 ▲ UP 1.39% (+$0.11)

OVERLAYS

About LeonaBio, Inc.

https://leonabio.com ↗

LeonaBio, Inc., a clinical-stage biopharmaceutical company based in Bothell, Washington, develops small molecules to restore neuronal health, with lead candidates ATH-1105 and ATH-1020 in phase 1 trials for neurodegenerative diseases.

INDUSTRY

Biotechnology

A PRODUCT LEONABIO, INC. IS KNOWN FOR

Lasofoxifene

Lasofoxifene, a Phase 3 investigational SERM targeting ER+/HER2- metastatic breast cancer with ESR1 mutations, is a key asset that transformed LeonaBio (formerly Athira Pharma) into an oncology-focused company.